Dr. Govindan on the Phase I Results of AMG 510 Evaluated in NSCLC
Ramaswamy Govindan, MD, professor of medicine, Washington University School of Medicine discusses the results of a phase I study looking at safety, tolerability, pharmacokinetics, and efficacy of KRAS G12C inhibitor, AMG 510 in patients with non-small cell lung cancer.
Ramaswamy Govindan, MD, professor of medicine, Washington University School of Medicine discusses the results of a phase I study looking at safety, tolerability, pharmacokinetics (PK), and efficacy of KRAS G12C inhibitor, AMG 510 in patients with non—small cell lung cancer. (NSCLC).
The study enrolled 38 patients with KRAS G12C mutation and adenocarcinoma, says Govindan. More than 85% of them had more than two prior lines of therapy, making this a typical group of patients with NSCLC. However, the findings thus far have not been typical.
AMG 510 was found to be well tolerated and showed antitumor activity. The investigators hope to see similar trends regarding safety, PK, and efficacy when more data becomes available.
